secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001619856-23-000112
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie terminates collaboration with Caribou for two allogeneic CAR-T programs; effective Oct 25, 2023
--------------------------------------------------------------------------------

- AbbVie exercised termination for convenience, citing strategic focus; not related to Caribou's performance or data.
- Termination effective October 25, 2023; all licenses under the 2021 Collaboration and License Agreement will end.
- Two preclinical allogeneic CAR-T programs targeting a single cancer target or target combination will be discontinued.
- No financial terms of termination disclosed; Caribou loses potential milestones and royalties from AbbVie programs.
- Caribou retains its Cas12a chRDNA genome-editing and CAR-T technologies for other partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000112/0001619856-23-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000112/crbu-20230926.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer